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Abstract
Staphylococcus aureus remains a leading cause of hospital-acquired and community-associated infection worldwide. The burden of disease is
exacerbated by the emergence of virulent strains with reduced susceptibility to commonly used antibiotics and their dissemination in
healthcare settings and in the community. Whole genome sequencing (WGS) has the potential to revolutionize our understanding and
management of S. aureus infection. As a research tool, WGS has provided insights into the origins of antibiotic-resistant strains, the genetic
basis of virulence, the emergence and spread of lineages, and the population structure of S. aureus. As a frontline tool, WGS offers the
prospect of a method that could be used to predict resistance, assess virulence, and type isolates at the highest possible resolution. The
results generated could be used to guide clinical management and infection control practice. Studies using bench-top sequencing machines
have already demonstrated the feasibility of such approaches. Infection control management is compromised by our incomplete
understanding of transmission, which in turn reﬂects the suboptimal resolution offered by conventional typing methods. As the costs of
sequencing begin to approach those of conventional methods, high-resolution typing with WGS could realistically be implemented for
hospital infection control, as well as for local and national surveillance practice. Translation into routine practice will require the
development of a knowledge base, reliable automated bioinformatic tools, the capacity to store, exchange and interrogate large volumes of
genomic data, and an acceptance of WGS by clinicians, infection control specialists, and laboratory staff.
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Introduction
Whole genome sequencing (WGS) allows comparison of the
genetic differences between organisms down to the resolution
of a single base pair. WGS is becoming faster and cheaper. It is
already possible, with bench-top machines, to turn around
sequence analysis of Staphylococcus aureus within days [1]. The
sequence assembly of a genome of approximately 3 9 106 bp
currently costs c. €60 ($75) with next-generation sequencing
platforms. This reﬂects a 400-fold reduction in costs as
compared with only 8 years ago [2]. It seems reasonable to
predict that costs will soon match those of conventional typing
techniques [3]. With increasing affordability, it is conceivable
that sequence-based methods might eventually replace tradi-
tional ones, not only for reference purposes, but also for
frontline diagnostics. Meanwhile, WGS is proving to be a
valuable research tool that can enhance our understanding of
bacterial population structure, evolution, pathogenesis, and
virulence. We review some recent research, and suggest how
WGS could be deployed in diagnostic laboratories (Table 1).
We describe some of the hurdles that might impede deploy-
ment, and outline the advantages over conventional methods.
Alexander Ogston drew attention to ‘staphylococcus’ as an
agent of postsurgical sepsis more than 100 years ago [4].
S. aureus continues to cause life-threatening invasive disease
worldwide [5,6]. Mortality rates for bacteraemia remain high,
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at 30% [7]. Prompt effective antibiotic treatment is important
in order to optimize clinical outcome [8]. Hence, clinicians
need reliable rapid tests to determine susceptibility. Increasing
awareness of methicillin-resistant S. aureus (MRSA) as an agent
of nosocomial infection has made disease prevention and
control key targets in many countries. The control and
management of S. aureus infections is hindered by incomplete
understanding of pathogenesis and virulence, and by limitations
in our ability to characterize highly related strains with
sufﬁcient resolution to inform on routes of transmission.
S. aureus strains can be assigned to lineages (or clonal
complexes (CCs)) that share characteristics because of
common descent [9–11]. Conventional typing techniques such
as multilocus sequence typing and spa typing rely on variation
in one or more genes to allocate strains to lineages. The short
sequences (400–4000 bp) characterized by conventional typing
methods account for only a fraction of the whole genome
(c. 2.8 million nucleotides) [12]. In suitably equipped labora-
tories, spa typing can be turned around rapidly. However, such
methods must be performed as an adjunct to conventional
frontline methods of identiﬁcation and characterization. It may
take weeks before informative results can be obtained from a
reference laboratory (Fig. 1). WGS offers the prospect of a
frontline method that could enable species identiﬁcation and
prediction of antibiotic resistance combined with high-resolu-
tion typing in a single rapid test.
Understanding and Predicting Antimicrobial
Resistance
Knowledge of the genetic basis of resistance will allow the
development of WGS-based approaches to antibiotic resis-
tance testing and will aid drug discovery. As a research tool,
WGS has been used to conﬁrm previous assumptions made
about mechanisms of antibiotic resistance, and has also
provided novel insights. For example, sequencing technologies
have conﬁrmed that S. aureus can acquire methicillin resistance
as a result of interspecies transfer of mecA from Staphylococcus
epidermidis [13]. Similarly, sequencing technology has con-
ﬁrmed that vancomycin-resistant S. aureus strains acquired
resistance genes from enterococci [14,15]. In addition, WGS
has shown that individual and accumulated point mutations are
also associated with reduced glycopeptide susceptibility [16–
18]. Sequencing of serial isolates from patients treated with
daptomycin showed that mutations in phospholipid biosynthe-
sis pathways are associated with reduced susceptibility [19].
S. aureus strains can become co-resistant to daptomycin and
vancomycin as a consequence of exposure to vancomycin
alone. In a study of isolates collected from a patient being
treated with vancomycin, WGS demonstrated the appearance
of mutations coincident with the emergence of daptomycin
resistance [18].
WGS could also be developed into a tool to guide clinical
decision-making for the care of individual patients by interro-
gation of the entire genome for the presence of mobile genetic
elements or point mutations known to confer resistance. This
comes at almost no additional cost to the initial costs of
sequencing, and potentially could be more rapid than tradi-
tional culture-based methods and more comprehensive than
PCR-based methods. In addition, a genetic method could be
less prone to user errors such as inaccuracies in measuring
inoculum densities or zone sizes.
In the context of MRSA outbreak investigations, it has been
shown that in silico interrogation of WGS data can reliably
predict antibiotic susceptibility phenotype [1,20]. A study using
a panel of 18 genes associated with resistance to ten
commonly used antistaphylococcal agents yielded overall
sensitivity and speciﬁcity of >95% (IDweek 2012,
abstract 35530). These results are comparable with those
obtained by phenotypic methods such as Vitek [21], and
provide further support for the use of WGS as a ﬁrst-line
screening method. The sensitivity can be increased by the
addition of further genes to the panel at no extra cost, and
previously sequenced isolates can be screened almost instantly
for newly recognized resistance genes.
However, the potential to predict phenotype from genetic
information is contingent on a thorough knowledge of
resistance mechanisms. Before this can occur, a robust
evaluation of the relationship between the ‘resistome’ as
determined by WGS and current reference standard pheno-
typic methods will be necessary, analogous to the ongoing
work required to determine breakpoints used in broth dilution
or disk diffusion methods. An up-to-date accessible database of
resistance genes will also be needed.
It is unlikely that in silico prediction will entirely replace
culture as a predictor of clinical response to therapy, as the
TABLE 1. Current and realistic future uses of whole genome
sequencing in the management of Staphylococcus aureus
infection
Current uses Potential uses
Outbreak analysis (retrospective) Rapid species identiﬁcation
Epidemiological surveillance (retrospective) Antibiotic susceptibility testing
Genome-wide association studies Detecting virulence determinants
Reference genomes Epidemiological surveillance
(local, national, global)
Outbreak detection (at point of
ﬁrst secondary case)
Host–pathogen relationship
Global standard for typing isolates
Culture-free sequencing
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presence or absence of a gene does not always correlate with
susceptibility. Detection of heteroresistance or resistance
resulting from two or more point mutations will be particularly
problematic. Initially, at least, isolates will need to be reported
as ‘potentially resistant’ or ‘potentially susceptible’, with
follow-up culture required for conﬁrmation. This is especially
true for infections where management is reliant on precise
knowledge of antibiotic susceptibility. However, as data
accumulate and a comprehensive database of resistance genes
is developed, the conﬁdence with which resistance can be
predicted will increase. Further investigation is required to
determine to what extent we will be able to rely on genotype
alone. Such approaches could be implemented for frontline
testing, while culture methods could be redeployed for
reference use and for ongoing surveillance for novel or
emerging resistance.
Understanding and Predicting Virulence
Genome-wide association studies have the potential to
uncover the genetic basis of severe disease. Analysis of
clinically relevant isolates has revealed genetic determinants of
virulence [22]. The sequencing and annotation of the ﬁrst two
complete S. aureus genomes resulted in the discovery of 70
novel candidate virulence factors [12]. Investigation of an
MRSA strain by Baba et al. [23] identiﬁed 19 additional
virulence factors. Comparison of three sequential S. aureus
isolates from a persistently colonized cystic ﬁbrosis patient
revealed patterns of gene diversiﬁcation that provided insights
into the genetic basis of adaptation during chronic infection
[24]. Such studies cast light on the relationship between
genotype and clinical phenotype. K€oser et al. [20] showed that
in silico interrogation of the S. aureus genome for known
virulence determinants could be used as an alternative to
conventional PCR-based methods. Results can be generated
rapidly with bench-top platforms, and offer the advantage of
providing information on toxin genes, antibiotic resistance
determinants and a measure of relatedness to other isolates
from a single test [2].
Infection Control in Hospitals
WGS can be used to track transmission within a hospital and
to assess the importance of patients, healthcare workers,
visitors and the hospital environment as potential sources or
vectors. With sequence data from serial carriage isolates, the
point mutation rate of S. aureus was estimated to be 2.72
mutations per megabase per year [25]. This resembles other
Organism growth detected from culture  
Antibiotic susceptibility
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FIG. 1. A comparison of methods used to identify and characterize Staphylococcus aureus, including (i) existing microbiological methods, (ii)
currently evaluated whole genome sequencing (WGS) techniques, and (iii) potential future applications of WGS. MLST, multilocus sequence typing;
MLVA, multiple-locus variable-number tandem-repeat analysis; PFGE, pulsed-ﬁeld gel electrophoresis.
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estimates, and equates to one mutation per genome roughly
every 7 weeks [26]. Hence, single-nucleotide variants (SNVs)
can be used like a molecular clock to measure the length of
time that has passed since two isolates shared a common
ancestor, and make inferences about short-term transmission.
Interpretation must take into account the possibility of
recombination events that result in large genetic differences
(>100 bp) between closely related strains. Bioinformatic
software is used to detect recombination events. Outbreaks
are generally detected through recognition of increasing
numbers or clustering of cases caused by a particular strain
type [27]. Through prospective analysis, the resolution offered
by WGS makes it possible to recognize newly emerging
strains, even when they belong to prevalent lineages of
S. aureus. Harris et al. [26] demonstrated the presence of a set
of genetically related isolates ( 14 SNVs) occurring among
members of the same lineage (ST239) that was prevalent in a
Thai hospital. Hence, WGS can be used to reveal transmission
networks that might remain undetected with conventional
methods [20]. WGS can also link genetically related isolates of
different phenotypes. Eyre et al. [1] investigated a suspected
outbreak involving heteroresistant MRSA, and showed that,
despite differences in antibiotic susceptibility, all isolates were
genetically highly related (0–3 SNVs). Differences in penicillin
and tetracycline susceptibility were shown by in silico interro-
gation of whole genome data to be attributable to the
presence or absence of mobile genetic elements bearing blaZ
or tetK. Price et al. (IDweek 2012, abstract 35917) used WGS
to investigate the role of colonized patients as potential
sources of new S. aureus acquisition by other inpatients. A
conventional typing method (spa typing) revealed an epidemi-
ologically related cluster of acquisition of the same spa type,
suggesting the possibility of a ward-based outbreak. However,
whole genome data showed the majority of these isolates to
be genetically too distant to be involved in recent transmission
events. Such isolates may represent wider networks of
transmission and acquisition in the hospital and the local
community. Conversely, as a result of mutations affecting the
spa gene, isolates that belong to different spa types may, in fact,
be closely related and involved in transmission networks.
WGS makes it possible to resolve such anomalies.
Epidemiological surveillance, population structure, and
biology
WGS offers the prospect of a portable high-resolution typing
method for surveillance of S. aureus locally, regionally, and
globally [26,28]. Coupled with syndromic surveillance, this
would allow precise tracking and monitoring of strains, and
assessment of their clinical signiﬁcance, and could provide early
warning of emerging pathogenic clones. The variety of
conventional molecular methods has resulted in differing
strain nomenclature and difﬁculties in communication of data
[3]. Standardized WGS nomenclature, data transfer and
interpretative algorithms could provide an enhanced global
surveillance system. Early identiﬁcation of newly emerging
strains could allow the prompt implementation of targeted
infection control resources.
S. aureus evolves primarily through point mutation, and has
a clonal population structure. Clones undergo periods of
emergence, expansion, and decline [29]. Currently, two
epidemic MRSA (EMRSA) lineages predominate in the UK;
EMRSA-15 (ST22, CC22) and EMRSA-16 (ST36, CC30).
Conventional techniques lack the necessary resolution to
investigate strain dynamics within these lineages. Using WGS,
Miller et al. (submitted) identiﬁed clonal expansion within a
dominant lineage (ST36, EMRSA-16) that explained excess
cases of invasive disease within a single hospital.
WGS is starting to allow us to understand the genetic basis
behind the emergence of successful strains. Isolates of different
lineages show genetic variation [30]. Some strains spread
globally and cause epidemics [31]. WGS has been used to
investigate community-associated MRSA, including the USA300
strain as an agent of skin and soft tissue infection [32,33]. Vogel
et al. [34] used WGS to investigate the South German clone
(ST228, spa t041) in a Swiss tertiary centre. Isolates associated
with persistent colonization showed such genetic features as
short-sequence indels, plasmid replacement, and movement of
mobile genetic elements, thus providing clues about the genetic
basis of a colonizing phenotype.
Culture-free Sequencing and Metagenomics
Current evaluations depend on the preparation of DNA from
cultured isolates. It may eventually become practicable to
sequence the entire complement of DNA in a clinical sample
directly, and to identify and characterize the organisms in it
that are known to be of medical importance. The application of
rapid direct sequencing to blood cultures, for example, might
improve the outcomes of patients with S. aureus infection [8].
Additionally, metagenomic analysis of clinical samples will allow
investigation of the interactions of multiple organisms during
health and disease. Metagenomic approaches are being devel-
oped in the ﬁeld of soil microbiology, where the majority of
species cannot be cultured with conventional methods. Many
environmental organisms produce antimicrobial substances,
and metagenomic methods could be used to identify such
compounds. Recently, two new antibiotics with activity against
MRSA, fasamycin A and B, have been identiﬁed with metage-
nomic analysis [35].
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Hurdles
Some obstacles need to be overcome before WGS can be
translated from the research arena into the routine laboratory.
At present, considerable bioinformatic expertise is required in
order to assemble a whole genome sequence. The currently
available platforms generate multiple short read lengths that
must be mapped to a reference genome or assembled de novo
by matching overlapping sequences. Mapping-based assembly
tends to leave gaps when sequences present in test isolates fail
to match reference genome sequences, and de novo methods
tend to generate incompletely resolved results. Hence, analysis
and interpretation require a high level of bioinformatic input to
generate information that is comprehensible to the infection
specialist. We believe that these difﬁculties will be ameliorated
by the development of software solutions that allow semi-
automated sequence assembly, analysis, and presentation of
results. This will be helped by machines that produce longer
read lengths.
We are still learning how to interpret the signiﬁcance of
SNV differences between isolates. Wide genetic divergence
between isolates from different patients reliably excludes the
possibility of recent transmission, and there can be reasonable
conﬁdence that pairs of genetically identical or highly related
isolates indicate recent transmission. However, Golubchik
et al. (unpublished observations) have detected genetically
divergent strain subpopulations in single patients. Another
potential confounding factor relates to calibration of the
molecular clock, as there is evidence of rapid micro-evolution
during invasive disease [25].
Another issue is the possibility of laboratory cross-contam-
ination when multiple isolates from suspected outbreaks are
handled. Hence, the development of WGS as an infection
control tool will require carefully controlled and validated
methods for sampling, culture, and analysis. Also, the scale of
information technology infrastructure required to store and
exchange the large quantities of data generated by WGS
cannot be underestimated.
Conclusion
WGS has the potential to transform the management of
S. aureus infection. Rapid prediction of resistance could improve
clinical outcome by permitting earlier effective management.
WGS allows characterization of transmission routes to opti-
mize infection control strategies and manage outbreaks. With a
clearer understanding of the genetic basis of virulence, WGS-
based surveillance could permit early determination of emerging
virulent strains (and new virulence genes) locally and globally.
Additionally, characterizing genetic diversity over time will
provide new insights into S. aureus population structures,
allowing us to understand the genetic basis of epidemics and
strain success. Already, the hurdles limiting the translation of
WGS into the routine microbiology laboratory are being
addressed. The concept of WGS in routine daily practice is
becoming a reality.
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